SCHEMBL30730610

SCHEMBL30730610

Cc1nonc1CC(=O)N1CCCC(c2nc(-c3ccc(F)cc3)no2)C1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.66
CLPP Q16740 1/20 0.66
MAPK1 P28482 4/20 0.62
MAPT P10636 1/20 0.62
POLB P06746 3/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
TSHR P16473 5/20 0.60
LMNA P02545 4/20 0.60
HSD11B1 P28845 1/20 0.60
CYP1A2 P05177 2/20 0.59
CYP3A4 P08684 2/20 0.59
CYP2C9 P11712 2/20 0.59
CYP2C19 P33261 2/20 0.59
ALDH1A1 P00352 4/20 0.59
HTT P42858 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
PKM P14618 1/20 0.58
RAB9A P51151 1/20 0.57
ALOX15 P16050 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730465 0.91 TSHR (0.56) GRM5CLPPMAPK1MAPTPOLB
SCHEMBL30730686 0.91 HSD11B1 (0.65) MAPK1TSHRLMNAHSD11B1ALDH1A1
SCHEMBL30730662 0.90 LMNA (0.71) GRM5CLPPMAPK1MAPTMEN1
SCHEMBL194186 0.86 GRM5 (0.74) GRM5CLPPMAPK1MAPTPOLB
SCHEMBL194185 0.86 GRM5 (0.74) GRM5CLPPMAPK1MAPTPOLB
SCHEMBL30730554 0.84 TSHR (0.51) GRM5CLPPMAPK1MAPTPOLB
SCHEMBL30730477 0.84 LMNA (0.55) GRM5CLPPMAPK1MAPTPOLB
SCHEMBL30730611 0.82 TSHR (0.48) GRM5CLPPMAPK1MAPTPOLB
SCHEMBL30730653 0.82 LMNA (0.53) GRM5CLPPMAPK1MAPTPOLB
SCHEMBL30730694 0.81 LMNA (0.62) GRM5CLPPMAPK1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 GRM5 4305/4885CLPP 4284/4885MAPK1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.